Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
Abstract Introduction Long-term complications of chronic hepatitis B (CHB) viral infection, such as cirrhosis, hepatocellular carcinoma (HCC), and liver failure, cause a large disease burden. This study aimed to describe the epidemiology, clinical outcomes, and treatment patterns of CHB infection an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-09-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-023-00860-8 |
| _version_ | 1797647247124463616 |
|---|---|
| author | Yuri Cho SeongBeom Park SeonYoung Park WonJung Choi Book Kim Helin Han |
| author_facet | Yuri Cho SeongBeom Park SeonYoung Park WonJung Choi Book Kim Helin Han |
| author_sort | Yuri Cho |
| collection | DOAJ |
| description | Abstract Introduction Long-term complications of chronic hepatitis B (CHB) viral infection, such as cirrhosis, hepatocellular carcinoma (HCC), and liver failure, cause a large disease burden. This study aimed to describe the epidemiology, clinical outcomes, and treatment patterns of CHB infection and co-infection with hepatitis D virus (HDV) in South Korea. Methods The retrospective, observational study used existing data from the Health Insurance Review and Assessment Service (HIRA) database. Confirmed cases of (CHB) and HBV/HDV co-infection were identified between 2013 and 2019. Hepatitis C virus co-infections and acute HBV infections were excluded. Incident cases diagnosed between 2015 and 2018 with no prior disease history up to 2 years were included. Patient characteristics, clinical outcomes, economic burden, and healthcare-resource utilization were described. Results The estimated 7-year prevalence of CHB and HBV/HDV co-infection were 0.9% and 0.0024%, respectively. The prevalence was higher among 45–54 years old (CHB: 1.6%, HBV/HDV: 0.0049%) and males (1.1%, 0.0035%). The 5-year cumulative incidences of compensated cirrhosis, decompensated cirrhosis, HCC, and liver transplantation were 13.3%, 7.1%, 8.4%, and 0.7%, respectively. Hyperlipidemia (40.6%), hypertension (23.5%), and peptic ulcer (23.7%) were the more prevalent comorbidities. Among CHB patients, 48.1% received ≥ 1 prescribed anti-HBV drug including interferon or nucleos(t)ide analogues and 64.4% had ≥ 1 hospitalization compared to 80.4% and 79.4% HBV/HDV patients. Estimated total healthcare costs for CHB and HBV/HDV were US$786 million and $62 million, respectively. Conclusions These findings provide insights to the epidemiology, clinical burden, treatment patterns, and healthcare costs of CHB and HBV/HDV co-infection in South Korea. |
| first_indexed | 2024-03-11T15:13:29Z |
| format | Article |
| id | doaj.art-32b672cc473e42eba3747baa7bc1e51e |
| institution | Directory Open Access Journal |
| issn | 2193-8229 2193-6382 |
| language | English |
| last_indexed | 2024-03-11T15:13:29Z |
| publishDate | 2023-09-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj.art-32b672cc473e42eba3747baa7bc1e51e2023-10-29T12:31:12ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822023-09-0112102387240310.1007/s40121-023-00860-8Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South KoreaYuri Cho0SeongBeom Park1SeonYoung Park2WonJung Choi3Book Kim4Helin Han5Center for Liver and Pancreatobiliary Cancer, National Cancer CenterJanssen PharmaceuticalsJanssen PharmaceuticalsJanssen PharmaceuticalsCerner EnvizaCerner EnvizaAbstract Introduction Long-term complications of chronic hepatitis B (CHB) viral infection, such as cirrhosis, hepatocellular carcinoma (HCC), and liver failure, cause a large disease burden. This study aimed to describe the epidemiology, clinical outcomes, and treatment patterns of CHB infection and co-infection with hepatitis D virus (HDV) in South Korea. Methods The retrospective, observational study used existing data from the Health Insurance Review and Assessment Service (HIRA) database. Confirmed cases of (CHB) and HBV/HDV co-infection were identified between 2013 and 2019. Hepatitis C virus co-infections and acute HBV infections were excluded. Incident cases diagnosed between 2015 and 2018 with no prior disease history up to 2 years were included. Patient characteristics, clinical outcomes, economic burden, and healthcare-resource utilization were described. Results The estimated 7-year prevalence of CHB and HBV/HDV co-infection were 0.9% and 0.0024%, respectively. The prevalence was higher among 45–54 years old (CHB: 1.6%, HBV/HDV: 0.0049%) and males (1.1%, 0.0035%). The 5-year cumulative incidences of compensated cirrhosis, decompensated cirrhosis, HCC, and liver transplantation were 13.3%, 7.1%, 8.4%, and 0.7%, respectively. Hyperlipidemia (40.6%), hypertension (23.5%), and peptic ulcer (23.7%) were the more prevalent comorbidities. Among CHB patients, 48.1% received ≥ 1 prescribed anti-HBV drug including interferon or nucleos(t)ide analogues and 64.4% had ≥ 1 hospitalization compared to 80.4% and 79.4% HBV/HDV patients. Estimated total healthcare costs for CHB and HBV/HDV were US$786 million and $62 million, respectively. Conclusions These findings provide insights to the epidemiology, clinical burden, treatment patterns, and healthcare costs of CHB and HBV/HDV co-infection in South Korea.https://doi.org/10.1007/s40121-023-00860-8Chronic hepatitis BHBV/HDV co-infectionsEpidemiologyClinical burdenHealthcare resource utilization |
| spellingShingle | Yuri Cho SeongBeom Park SeonYoung Park WonJung Choi Book Kim Helin Han Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea Infectious Diseases and Therapy Chronic hepatitis B HBV/HDV co-infections Epidemiology Clinical burden Healthcare resource utilization |
| title | Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea |
| title_full | Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea |
| title_fullStr | Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea |
| title_full_unstemmed | Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea |
| title_short | Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea |
| title_sort | real world epidemiology treatment patterns and disease burden of chronic hepatitis b and hdv co infection in south korea |
| topic | Chronic hepatitis B HBV/HDV co-infections Epidemiology Clinical burden Healthcare resource utilization |
| url | https://doi.org/10.1007/s40121-023-00860-8 |
| work_keys_str_mv | AT yuricho realworldepidemiologytreatmentpatternsanddiseaseburdenofchronichepatitisbandhdvcoinfectioninsouthkorea AT seongbeompark realworldepidemiologytreatmentpatternsanddiseaseburdenofchronichepatitisbandhdvcoinfectioninsouthkorea AT seonyoungpark realworldepidemiologytreatmentpatternsanddiseaseburdenofchronichepatitisbandhdvcoinfectioninsouthkorea AT wonjungchoi realworldepidemiologytreatmentpatternsanddiseaseburdenofchronichepatitisbandhdvcoinfectioninsouthkorea AT bookkim realworldepidemiologytreatmentpatternsanddiseaseburdenofchronichepatitisbandhdvcoinfectioninsouthkorea AT helinhan realworldepidemiologytreatmentpatternsanddiseaseburdenofchronichepatitisbandhdvcoinfectioninsouthkorea |